Track market-moving stories before they get noisy

Explore the exciting world of Moderna (MRNA -5.17%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System raised its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 31.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 628,160 shares of the company’s stock after purchasing an additional 149,192 shares during the quarter. California Public Employees Retirement System owned 0.16% of Moderna worth $31,911,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of MRNA. Canton Hathaway LLC bought a new position in shares of Moderna during the 1st quarter worth approximately $31,000. Assetmark Inc. lifted its position in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares in the last quarter. MUFG Securities EMEA plc bought a new stake in shares of Moderna in the second quarter worth $28,000. Flagship Harbor Advisors LLC acquired a new position in Moderna during the fourth quarter worth $31,000. Finally, Cromwell Holdings LLC boosted its holdings in Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance Shares of MRNA opened at $59.66 on Wednesday. The company has a market cap of $23.67 billion, a PE ratio of -7.32 and a beta of 0.94. The firm has a 50-day moving average of $58.13 and a 200-day moving average of $51.36. Moderna, Inc. has a one year low of $22.28 and a one year high of $85.60. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same period in the previous year, the company posted ($2.52) earnings per share. The firm’s revenue for the quarter was up 260.2% compared to the same quarter last year. As a group, equities analysts forecast that Moderna, Inc. will post -6.41 earnings per share for the current year.

Insiders Place Their Bets In other news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Abbas Hussain sold 5,682 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $46.63, for a total value of $264,951.66. Following the transaction, the director directly owned 12,066 shares in the company, valued at $562,637.58. The trade was a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,088 shares of company stock worth $6,193,713 in the last three months. 10.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth Several equities research analysts have commented on MRNA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Bank of America raised their price objective on Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a report on Thursday, June 18th. Wolfe Research reissued an “underperform” rating and set a $25.00 price target on shares of Moderna in a research report on Monday. Finally, The Goldman Sachs Group raised their price target on Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $40.00.

Get Our Latest Research Report on MRNA

Moderna Company Profile (Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Featured Articles Five stocks we like better than Moderna Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Grows Position in J.B. Hunt Transport Services, Inc. $JBHT

NEXT HEADLINE »Andra AP fonden Increases Stake in Marvell Technology, Inc. $MRVL

Moderna (MRNA 3.77%) soared onto the scene in early pandemic days with its messenger RNA technology and delivered a coronavirus vaccine in a matter of months. As the vaccine brought in blockbuster revenue, Moderna's stock price roared higher. In fact, from the start of 2020 through early August 2021, it climbed more than 2,000%.

In recent years, as demand for the coronavirus vaccine declined, the biotech company also saw its profits shrink and even turn into losses. And though the pipeline remained robust, investors had difficulty seeing Moderna as more than a coronavirus vaccine player. All of this led to declines in the stock price, with it sliding more than 80% from its peak.

But Moderna has made significant progress advancing pipeline programs and cost-cutting efforts, and this year, investors have been sitting up and taking notice. The stock has skyrocketed, climbing 109%. Jim Cramer of CNBC's Mad Money calls it "finally investable again." Is Moderna a no-brainer buy on its recent pullback? Let's find out.

Image source: Getty Images.

Moderna's disappointments As mentioned, Moderna struggled in recent years as it took time to transition from a coronavirus vaccine company to a player that investors could see as a multi-product company across treatment areas. Moderna faced its share of disappointments along the path, too, with its respiratory syncytial virus (RSV) vaccine delivering sales that fell short of expectations during its first season on the market and its cytomegalovirus (CMV) candidate failing in late-stage trials.

These sorts of setbacks aren't uncommon for biotech and pharma companies, but following the decline in coronavirus vaccine sales, they added to Moderna's difficulties. But the biotech company progressed in its efforts to realign costs with its opportunities and advance promising programs.

In the latest quarterly update, Moderna reiterated its goal of generating as much as 10% revenue growth this year. And in the quarter, the company delivered a 26% reduction in adjusted cash costs.

Moderna currently has three approved products in the U.S. -- two coronavirus vaccines and its RSV vaccine -- and it may be on the way to launching a fourth. Regulators currently are reviewing the company's flu vaccine candidate, mRNA-1010, and a decision is expected on or before Aug. 5. The company also recently won approval in Europe for its combined coronavirus/flu vaccine -- the world's first.

Today's Change

(

-3.77

%) $

-2.33

Current Price

$

59.49

Future growth drivers Moderna's late-stage candidates and commercialized medicine focus areas are infectious disease vaccines, rare diseases, and oncology. And here, late-stage candidates may drive significant growth in the coming years. For example, intismeran autogene, a personalized cancer therapy, is being studied in several phase 3 trials, and the company's propionic acidemia study is fully enrolled, with data expected later this year. This study may support a regulatory submission.

"Moderna's got a plethora of thoughtful, new products and clear roadmap to profitability for the first time in such a long time," said CNBC's Jim Cramer.

Meanwhile, Moderna stock, though it's soared more than 100% this year, has declined 24% from a peak on July 6. Is the stock a no-brainer buy after this pullback? Moderna is a buy, but investors shouldn't rush to get in on the stock immediately. At today's level, it's reasonable to pick up the shares, but I wouldn't expect them to soar overnight to an out-of-reach price.

Your decision may depend on your investing strategy. Cautious investors might wait a bit longer as Moderna's late-stage candidates progress and then consider picking up a few shares. Aggressive investors, however, may aim to start building a position today, on the dip, and potentially add to this position over time.

Even if Moderna's performance in the second half of the year isn't as spectacular as it was in the first half, that's OK -- the company clearly has reached a key transition point on its path to becoming a multi-product player addressing numerous treatment areas. And that makes it a fantastic stock to buy now or in the coming quarters and hold onto for the long term.

Key Takeaways Moderna dosed the first U.S. participant in a phase I study of mRNA-4200 for advanced solid tumors.MRNA-4200 targets seven shared tumor antigens and is being studied with checkpoint inhibitor therapy.Moderna's Horizon 2 strategy includes mRNA-4200 and other early-stage oncology programs beyond vaccines. Moderna (MRNA - Free Report) announced that it has dosed the first U.S. patient in a phase I study evaluating mRNA-4200, an investigational off-the-shelf, tumor-targeted cancer antigen therapy.

The study will assess the safety and tolerability of the candidate administered in combination with checkpoint inhibitor therapy in adults with advanced solid tumors. mRNA-4200 is Moderna’s third off-the-shelf cancer antigen therapy candidate and reflects its efforts to broaden the application of mRNA-based immunotherapies in oncology.

mRNA-4200 was developed in collaboration with Immatics (IMTX - Free Report) using its proprietary platforms. The candidate encodes seven shared tumor antigens designed to induce and expand T-cell responses across multiple tumor types.

Year to date, MRNA's shares have skyrocketed 114.1%, compared with the industry’s 2.5% growth.

Image Source: Zacks Investment Research

mRNA-4200 Supports MRNA's Long-Term Diversification StrategyThe initiation of the phase I mRNA-4200 study is closely aligned with Moderna's recently announced long-term strategy to diversify beyond its traditional vaccine business. The company plans to leverage its messenger RNA (mRNA) platform across multiple therapeutic areas.

To execute this strategy, the company has organized its business into three development horizons. Horizon 1 comprises the company's commercial products and late-stage pipeline assets, including the Merck (MRK - Free Report) -partnered personalized cancer therapy and investigational rare disease programs.

Horizon 2 focuses on early-stage clinical programs that include cancer antigen therapies, T-cell engagers and cell therapy enhancers. The study initiation on mRNA-4200, which is part of this horizon, illustrates Moderna's strategy of extending its proven mRNA technology beyond infectious diseases into oncology, reinforcing the company's objective of building a diversified portfolio of innovative therapies.

Horizon 3 consists of earlier-stage research programs that have not yet entered clinical development. These include in vivo CAR-T and CAR-M cell therapies, which could become the company's next-generation growth platforms.

MRNA’s Zacks RankModerna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1(Strong Buy) Rank stocks here.

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company’s late-stage pipeline, including anticipated Phase III melanoma data.

Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.

The analysts forecast a loss of $1.99 per share on revenue of about $100 million, compared with consensus expectations for a loss of $1.97 per share.

“COVID sales are mostly weighted to H2 2026,” Jefferies wrote, noting that lower vaccination rates year-over-year are also expected to weigh on near-term revenue.

The firm expects management could reiterate its 2026 revenue outlook for growth of up to 10% year over year, which would imply revenue of more than $2.1 billion.

Jefferies said potential upside to Moderna’s 2026 sales outlook could come from stabilization in US COVID revenue, which declined from approximately $1.2 billion in 2025. The firm expects international partnerships, including those in Canada, Australia and the UK, to contribute to growth and help create a more balanced revenue mix between US and ex-US markets.

Investors are also watching Moderna’s pipeline progress, particularly Phase III data for mRNA-4157, the company’s personalized cancer vaccine candidate being evaluated in combination with Merck & Co.’s Keytruda in melanoma. Jefferies highlighted the upcoming Phase III INTerpath-001 trial data as a major potential catalyst for the stock, with results expected in the second half of 2026.

The analysts pointed to recent five-year Phase IIb data as supportive of the ongoing Phase III study in high-risk adjuvant melanoma, which enrolled 1,089 patients. Jefferies wrote that management appears confident in the timing of the readout based on event accrual and said a statistically significant result could have a meaningful impact on investor sentiment.

Beyond oncology, Moderna has several additional potential catalysts in 2026, including regulatory action for its mFluSiva flu vaccine candidate, which Jefferies expects could receive US approval by August 5 following a positive advisory committee review. However, the analysts expect commercial sales to begin in 2027.

The firm also highlighted potential Phase III updates for Moderna’s norovirus vaccine candidate mRNA-1403 and pivotal data for mRNA-3927, an investigational treatment for propionic acidemia, as additional events to watch later this year.

Jefferies noted that Moderna’s shares have outperformed the broader biotechnology sector year to date, gaining 124% compared with a 30% rise in the XBI biotechnology ETF, with much of the recent momentum tied to expectations around the company’s oncology pipeline and the potential of its mRNA technology platform.

Shares of Moderna traded hands at $67 on Tuesday afternoon.

Moderna (MRNA - Free Report) closed the most recent trading day at $66.98, moving -1.89% from the previous trading session. This change lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.

Prior to today's trading, shares of the biotechnology company had gained 36.79% outpaced the Medical sector's gain of 5.5% and the S&P 500's gain of 4.28%.

Market participants will be closely following the financial results of Moderna in its upcoming release. The company plans to announce its earnings on July 31, 2026. The company is predicted to post an EPS of -$1.97, indicating a 7.51% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $114.89 million, reflecting a 19.09% fall from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates are projecting earnings of -$8.34 per share and revenue of $2.08 billion, which would represent changes of -14.88% and +7.04%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.85% lower. Right now, Moderna possesses a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 44% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 11% to $68.50, ImmunityBio (NASDAQ:IBRX) shares are off 8% to $8.16, and Sarepta Therapeutics (NASDAQ:SRPT) stock has slid 8% to $18.84.

The moves are steep, but they land on top of extraordinary year-to-date gains. Moderna stock had climbed 160% year to date through Thursday’s close, and ImmunityBio shares were up 348% year to date heading into today. There’s no company-specific bad news attached to any of the three names.

The SPDR S&P Biotech ETF (NYSEARCA:XBI) is off 4% midday, framing this as a sector-wide flush rather than a single-name blowup. The equal-weighted sector proxy holds all three of today’s decliners among its constituents.

Profit-Taking After a Parabolic Run The cleanest read on today’s selloff in Moderna, ImmunityBio, and Sarepta and other biotechnology stocks is profit-taking and sector rotation after a parabolic run. Recent news flow on all three names was actually bullish, and no headline catalyst has surfaced to explain the move.

ImmunityBio has ridden Russell 1000 inclusion hopes and Anktiva optimism to its triple-digit gain, with Q1 2026 revenue of $44.21 million up 168% year over year and ANKTIVA unit sales up 168% year over year. Sarepta Therapeutics stock, meanwhile, was just upgraded by Wolfe Research to Outperform with a $27 target, implying 34% upside from Thursday’s close.

Moderna’s own Q1 2026 print was strong: revenue of $389 million beat the consensus estimate by 65%, and management reaffirmed up to 10% revenue growth for the year. The near-term catalyst is the mRNA-1010 seasonal flu vaccine PDUFA date of August 5.

Big Pharma Barely Flinches The rotation angle sharpens when you look outside biotech. Eli Lilly (NYSE:LLY) stock is down 3% midday, while Johnson & Johnson (NYSE:JNJ) shares are off by just 1%.

That gap tells the story. Money is coming out of high-beta, pre-profit biotech names and holding still in defensive large-cap pharma, where Eli Lilly stock is still up 10% year to date and Johnson & Johnson stock is up 24% year to date.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Moderna didn't make the cut. Grab the names FREE today.

XBI Puts the Selloff in Perspective The SPDR S&P Biotech ETF is the cleanest sector proxy since it holds Moderna, ImmunityBio, and Sarepta among its equal-weighted constituents. Even after today’s drop, XBI is still up 78% over the past 12 months.

Because the ETF is equal-weighted, its move reflects broad biotech weakness rather than one name driving the move. The fund isn’t leveraged, but it is a volatile sector vehicle, and today’s action is a reminder of how quickly biotech beta cuts both ways.

Moderna: Bull Case Meets Bear Case The bull case for Moderna leans on the pipeline. The August PDUFA on the flu vaccine, brands including Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX, and a year-end cash target of $4.5 billion to $5 billion give management runway. Reddit retail sentiment sits at 72, classified as bullish, framing the run as a “savage comeback” comparable to post-dotcom recovery.

The bear case is the price action. Moderna stock is down 71% over five years, cash burn remains heavy after a $1.34 billion GAAP net loss, and consensus analyst targets sit well below the current price. Investors may want to size their positions modestly given the high-beta profile visible in today’s move.

What to Watch Next The immediate tell is whether XBI stabilizes into the close or accelerates lower, which would signal the rotation has more room to run. Moderna’s August 5 PDUFA decision is the next hard-dated catalyst on the calendar for the primary name.

The takeaway: today’s slide in Moderna, ImmunityBio, and Sarepta looks like an unwind after a historic biotech rally rather than a fundamental rerating. Investors holding these names may want to reassess their position sizing given how quickly a sharp one-month gain in Moderna can compress into a double-digit down day.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Moderna didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesJuly 9 (Reuters) - Moderna (MRNA.O), opens new tab said on Thursday it has secured a European Commission contract to ​supply its respiratory syncytial virus vaccine ‌to six countries in the region.

Here are the details:

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The agreement gives the participating countries - Austria, ​Denmark, Ireland, Luxembourg, Norway and Portugal - ​access to up to 24 million ⁠doses of the vaccine over as ​many as four years, the company said.

The ​vaccine, mRESVIA, will be supplied in a ready-to-use, single-dose pre-filled syringe, making administration easier for healthcare ​professionals, Moderna said.

The company had a ​similar joint procurement framework agreement with the European ‌Commission ⁠for COVID-19 vaccines last year.

mRESVIA is authorized in the European Union to prevent lower respiratory tract disease caused by RSV ​in adults.

RSV ​is ⁠a common respiratory virus that causes seasonal infections such as ​the flu and is a leading ​cause ⁠of pneumonia and death in infants and older adults.

Moderna has four approved mRNA vaccines for ⁠respiratory ​infections, including a combined ​influenza and COVID-19 vaccine authorized in Europe.

Reporting by Christy ​Santhosh in Bengaluru; Editing by Leroy Leo

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Moderna's (MRNA +2.57%) share price has more than doubled this year as the market has grown increasingly optimistic about the company's pipeline and encouraging regulatory progress for its flu vaccine. But after such a sharp rally, it's fair to ask whether there's still an opportunity here to make some money.

What comes next for Moderna? The investment case for Moderna isn't just about COVID-19 vaccines anymore. It's about what comes next.

Today, the company has three commercial products, multiple late-stage vaccine programs, and an expanding pipeline that stretches well beyond infectious diseases. Moderna is developing personalized cancer vaccines in partnership with Merck and pursuing therapies for rare genetic disorders.

Image source: Getty Images.

The company is now preparing for multiple product launches in 2027 and 2028, including seasonal flu, a flu/COVID-19 combination vaccine, and a norovirus vaccine. That's a dramatically different company than the one investors knew during the pandemic, when nearly all of its revenue came from a single COVID-19 vaccine. If even a handful of these late-stage programs reach the market, Moderna could become a much more diversified biotechnology company with multiple sources of recurring revenue. And the financial picture is improving, too.

Possible breakeven by 2028 During the first quarter of 2026, Moderna generated $389 million in revenue, up from $108 million a year earlier. Although the company still posted a net loss, it finished the quarter with approximately $7.5 billion in cash and investments, providing it with ample resources to continue funding its research pipeline. Management also continues targeting up to 10% revenue growth in 2026 while working toward cash breakeven by 2028.

The biggest near-term catalyst may be the company's flu vaccine. An FDA advisory committee recently voted 9-0 to recommend approval for Moderna's seasonal influenza vaccine for adults 50 and older. While the FDA isn't required to follow the panel's recommendation, it often does, with a final decision expected in early August. Of course, that doesn't mean the stock is without risk.

Today's Change

(

2.57

%) $

2.05

Current Price

$

81.81

High expectations for Moderna Much of Moderna's recent rally reflects higher expectations, and several important clinical readouts (including late-stage melanoma data) are still ahead. Any disappointing results could quickly change investor sentiment. But it's still hard to justify passing on the stock, even after its latest run.

You see, Moderna is no longer just a play on COVID-19. It's actually becoming a highly successful, diversified biotechnology company with multiple opportunities to create value over the next several years. After such a strong run, don't expect the shares to move in a straight line. But if you're thinking long-term, Moderna still offers considerable upside.

Moderna (MRNA - Free Report) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day. This move outpaced the S&P 500's daily gain of 0.72%. Meanwhile, the Dow gained 0.3%, and the Nasdaq, a tech-heavy index, added 1.12%.

Prior to today's trading, shares of the biotechnology company had gained 68.13% outpaced the Medical sector's gain of 12.48% and the S&P 500's loss of 0.9%.

Market participants will be closely following the financial results of Moderna in its upcoming release. In that report, analysts expect Moderna to post earnings of -$2 per share. This would mark year-over-year growth of 6.1%. Meanwhile, our latest consensus estimate is calling for revenue of $114.89 million, down 19.09% from the prior-year quarter.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$8.33 per share and a revenue of $2.07 billion, indicating changes of -14.74% and +6.64%, respectively, from the former year.

Any recent changes to analyst estimates for Moderna should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Moderna presently features a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 150, finds itself in the bottom 40% echelons of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Key Takeaways Moderna outlined a strategy to expand its mRNA platform beyond vaccines into multiple therapies.Shares of the company rallied as Science Day spotlighted oncology, autoimmune and cell therapy programs.MRNA expects early-stage programs, including in vivo CAR-T and CAR-M therapies, to enter the clinic by 2027. Shares of Moderna (MRNA - Free Report) have surged 33.5% over the past week, adding nearly $8 billion to the company's market value.

The rally was sparked by Moderna's Science Day, where management outlined its vision to evolve beyond vaccines into a diversified biotechnology company. The event showcased how the company plans to leverage its messenger RNA (mRNA) platform across multiple therapeutic areas, including oncology, autoimmune diseases and cell therapy, while unveiling a new research and early development framework to accelerate pipeline innovation.

Moderna Leverages Its mRNA Platform Beyond VaccinesAs part of its long-term strategy, the company has grouped its business into three development horizons. Moderna emphasized that its commercial products, late-stage pipeline assets — including respiratory vaccine programs and its Merck (MRK - Free Report) -partnered personalized cancer therapy — as well as investigational rare disease therapies, represent Horizon 1, the foundation of its current business.

Beyond these established programs, Moderna introduced Horizon 2 and Horizon 3, underscoring its ambition to expand the application of its mRNA platform well beyond vaccines. Horizon 2 comprises emerging therapeutic modalities already in clinical development, including cancer antigen therapies, T-cell engagers, cell therapy enhancers and an investigational therapy for multiple sclerosis.

Horizon 3 comprises earlier-stage research programs that have not yet entered the clinic but are expected to advance into first-in-human studies before the end of 2027. These include in vivo CAR-T and CAR-M cell therapies, which could become the company's next-generation growth platforms.

Moderna is not alone in broadening the application of mRNA technology. The company’s rival BioNTech (BNTX - Free Report) is also leveraging its mRNA platform beyond vaccines and building an extensive pipeline across oncology and other disease areas to diversify its long-term growth prospects.

Why Investors Are Paying Attention to MRNA StockInvestors appear to have welcomed Moderna's efforts to expand the use of its mRNA platform beyond vaccines. Among the highlights was mRNA-6007, the company's first investigational in vivo CAR-T candidate for autoimmune diseases such as systemic lupus erythematosus (SLE), representing Moderna's entry into cell therapies. The program is part of the company's Horizon 3 pipeline, which management expects to advance into clinical studies by the end of 2027.

More broadly, the event underscored Moderna's strategy to use its mRNA platform to develop multiple classes of medicines spanning oncology, rare diseases, autoimmune disorders and cell therapies. By broadening the application of its mRNA platform across diverse therapeutic areas, the company aims to diversify future revenue streams beyond respiratory vaccines. The strategy appears to have resonated with investors, helping lift the stock to a 52-week high of $81.40.

MRNA’s Price Performance, Valuation & EstimatesShares of Moderna have skyrocketed more than 170% year today, significantly outperforming the industry’s 5.5% growth.

Image Source: Zacks Investment Research

From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 13.16 times forward 12-month sales, higher than the industry average of 1.91 times.

Image Source: Zacks Investment Research

Estimates for Moderna’s 2026 and 2027 bottom line have declined over the past 60 days.

Image Source: Zacks Investment Research

Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Moderna Inc. MRNA shares rose 9.2% on Thursday, making the biotechnology company one of the top performers in the S&P 500.

Investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary.

The stock extended its recent rally after climbing to a new annual high on Wednesday.

At one point, shares gained nearly 12% as investors welcomed the company's latest Science Day presentation and progress across its mRNA development programs.

Investor sentiment also received a boost after an FDA advisory panel unanimously supported Moderna's mRNA-1010/mFLUSIVA influenza vaccine for adults aged 50 to 64 and those 65 and older.

The recommendation comes ahead of a Prescription Drug User Fee Act (PDUFA) decision expected on Aug. 5, 2026, as well as planned global regulatory filings.

During its recent Science Day presentation, Moderna outlined plans to expand its mRNA platform beyond infectious disease vaccines into oncology, autoimmune diseases and other therapeutic areas.

The company showcased programs targeting multiple myeloma, ovarian cancer and in vivo CAR-T therapies, while emphasizing increased use of artificial intelligence, machine learning, automation and robotics to accelerate research and development.

Plans to begin the in vivo CAR-T program mRNA-6007 in 2027 also contributed to investor optimism.

Chief Executive Officer Stéphane Bancel said the company's strategy extends across multiple areas of development.

Working across three strategic horizons, we are applying our mRNA platform expertise to validate, scale and expand our modalities, with new modalities in the clinic, including T-cell engagers, and new modalities soon to be in the clinic, like in vivo CAR-T. At the same time, we are driving innovation by using data, AI and machine learning, and robotics to accelerate discovery and continuously improve how we execute for near-term growth while fuelling the next generation of mRNA medicines for patients around the world.

Analysts remained constructive on Moderna's long-term prospects despite differing views on the pace of commercialization.

Jefferies maintained a Hold rating and a $45 price target, stating that while eventual approval of the influenza vaccine appears likely, meaningful flu-related revenue is not expected until 2027.

Piper Sandler took a more optimistic stance, raising its price target to $77 from $69 while reiterating an Overweight rating following the recent rally.

The positive analyst commentary added to growing optimism surrounding Moderna's expanding pipeline beyond COVID-19 vaccines.

Financial position remains supported by cash reservesDespite renewed enthusiasm surrounding its research programs, Moderna continues to operate at a loss as it invests heavily in product development.

The company generated approximately $389 million in quarterly revenue and about $1.94 billion in trailing 12-month revenue.

However, it reported a net loss of roughly $1.34 billion in the latest quarter and an EBITDA loss of approximately $1.28 billion. Free cash flow stood at negative $692 million.

Moderna has approximately $5.21 billion in cash and short-term investments, a current ratio of 2.4 and long-term debt of about $1.25 billion, providing financial flexibility as it continues investing in its pipeline.

CNBC's Jim Cramer also expressed optimism about the company's direction.

“For the first time in a long time, the company seems like it has something to get excited about", Cramer said on Wednesday.

He added that Moderna's “plethora of thoughtful, new products” is presenting a clear roadmap to profitability for the first time in a long while.

However, Cramer also urged patience, saying, “I recommend waiting for a pullback before you buy. Take your time. I think Moderna’s got a bright future though, but it’ll take years to get there.”

After a significant slump following the height of the COVID-19 pandemic, Moderna (MRNA +0.53%) share prices have ripped higher over the past year, surging nearly 150%. Various factors have driven Moderna's rebound, including regulatory progress on one of its most anticipated products.

Yet even as this news, plus additional promising announcements, suggests a further recovery ahead for this pandemic-era favorite, keep in mind how much of this "comeback potential" is already priced into one of the hottest biotech stocks.

Image source: Getty Images.

Why Moderna is surging higher On June 18, Moderna disclosed how a Food and Drug Administration (FDA) advisory committee voted unanimously that the benefits of its mRNA-based flu vaccine, mRNA-1010, outweigh the risks among patients aged 50 or over. The FDA could approve mRNA-1010 as soon as Aug. 5. The candidate is also currently under regulatory review in Australia, Canada, and the European Union.

Today's Change

(

0.53

%) $

0.37

Current Price

$

70.07

Other news has also lifted sentiment. The company's recent investor day also included a surprise announcement that it is gearing up to develop an in vivo CAR-T candidate. Success with this endeavor could help Moderna diversify into respiratory, oncology, and rare-disease treatments.

Tread carefully amid the hype There's substance to the market's bullish shift on Moderna, but things have arguably gotten out of hand. After its hot run, the company now has a market cap of around $26.7 billion. As Moderna is currently unprofitable, this valuation is clearly based upon the future potential of its non-COVID-19 products. However, the estimated total addressable market for flu vaccines is only around $9.5 billion. Moderna will likely need to gain dominant market share for this to translate into sales and earnings that help justify the stock's current valuation.

Even when factoring in future potential with CAR-T and other treatments, many of these early products remain years away from commercialization. In the meantime, as Moderna continues to burn through its cash position to fund its post-COVID-19 comeback, the company could be at increased risk of a dilutive equity offering. Even if you're bullish on Moderna's long-term rebound potential, you may want to wait until some of the latest hype fades before buying.

Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Moderna. The Motley Fool has a disclosure policy.

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher on Monday. This follows Friday’s gain of more than 12%.

A classic ‘flag’ pattern has formed on the chart. In this situation, the pattern is bullish and suggests a continued move higher. This is why Moderna is the Stock of the Day.

If market leadership shifts from bulls to bears, or from bears to bulls, price action can appear as a reversal pattern on a chart.

If the change is slow and takes place over an extended period of time, a ‘rounded’ top or bottom may form. If the change occurs in a single day, a reversal day or an engulfing pattern may form.

The flag pattern isn’t a reversal pattern. It is a continuation pattern. These appear when the current trend takes a short break before getting back into gear. This flag pattern formed during an uptrend, which could mean the rally will continue.

Many technical analysts try to identify chart patterns without understanding the dynamics that make the pattern form.

A flag forms after a rapid move higher. Some of the buyers start to believe that they are the ones pushing the price up. They think that if they leave the market for a few days, the price will fall and they will be able to complete their orders at a lower price.

Because they step away, the price drops a little. When they come back into the market after a few days, the rally resumes.

The first defining characteristic of the flag pattern is a significant drop-off in volume. The second characteristic is the short time period. If these two conditions do not occur, then it is not a flag pattern.

Technical analysis has a dubious reputation, and unfortunately, it deserves it. Many analysts don’t understand the price action and dynamics that make chart patterns form. This is why they are not successful.

The flag pattern on the chart of Moderna could mean the shares will continue to move higher.

MRNA Price Action: Moderna shares were up 1.54% at $68.30 at the time of publication on Monday. The stock is trading near its 52-week high of $69.28, according to Benzinga Pro data.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.

Moderna (MRNA 1.03%) has been on fire this year. As of this writing, the company's shares have slightly more than doubled to date. What's more, the biotech has an important catalyst on the horizon. Let's find out whether there is any upside left for the company.

Image source: Getty Images.

Racing toward an approval Moderna has been working on an influenza vaccine, mRNA-1010. It submitted regulatory applications for this candidate earlier this year. The U.S. Food and Drug Administration (FDA) should approve or reject Moderna's application by Aug. 5. It's an important date for the biotech company, as an approval in this field might allow it to establish itself as a leader in the flu market. True, plenty of flu vaccines exist, but their efficacy is usually not very impressive, typically between 40% to 60% in the U.S. In phase 3 studies, mRNA-1010 performed better than approved vaccines in patients aged 50 and older who tend to be more at risk of severe cases of the disease, hospitalization, and death.

And if there was any doubt about whether mRNA-1010 would get the FDA's green light, recent developments have made that outcome practically certain. Members of an advisory committee convened by the FDA to give their opinion on whether mRNA-1010 should earn approval unanimously voted in favor. The health regulatory agency doesn't always follow the advice of these experts, but it almost always does. It would be surprising if mRNA-1010 doesn't get the nod.

Today's Change

(

-1.03

%) $

-0.62

Current Price

$

59.80

What does this mean for the stock? Moderna's shares soared after the advisory committee's vote of confidence for mRNA-1010. So, it's likely the market has already priced in a positive outcome, and the stock won't move much once mRNA-1010 is approved. However, there are still good reasons to invest in Moderna. The company is once again demonstrating its innovative qualities with mRNA-1010, just as it did with its coronavirus vaccine, which became a leader in that niche. The flu vaccine market isn't that large. According to some estimates, it was worth $8.9 billion last year, although it will continue growing at a good clip for the foreseeable future. Moderna's potential sales in this niche alone do not justify its $24.5 billion market cap, especially given that it generates meager revenue from its currently approved products.

That said, the vaccine maker has a rich pipeline with several products that could become key growth drivers. For instance, Moderna is developing mRNA-4157, an investigational personalized cancer vaccine that has shown highly encouraging clinical trial results and is now undergoing several phase 2 and phase 3 studies. Moderna is also going after difficult targets. The company is developing an HIV vaccine. Moderna's success in the flu vaccine market will help it pursue even more lucrative markets. Over the next five years, the company could have a much broader portfolio of approved products while generating strong revenue and earnings. That's why Moderna's shares are still attractive, even after climbing by about 100% this year.

Provides broad overview of Company's research and early development programs expected to continue to fuel future growth

Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer

Introduces in vivo CAR-T modality with mRNA-6007 moving into early development for autoimmune diseases

CAMBRIDGE, MA / ACCESS Newswire / June 25, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced research and early development updates at its Science Day event.

"As we execute our strategic plan to become a diversified, multi-modality biotechnology company, we are preparing to manage three commercial franchises, Infectious Disease Vaccines, Intismeran, and Rare Disease Therapeutics, while advancing a broad mRNA pipeline and continuing to invest in research and development," said Stéphane Bancel, CEO of Moderna. "Working across three strategic horizons, we are applying our mRNA platform expertise to validate, scale and expand our modalities, with new modalities in the clinic, including T-cell engagers, and new modalities soon to be in the clinic, like in vivo CAR-T. At the same time, we are driving innovation by using data, AI and machine learning, and robotics to accelerate discovery and continuously improve how we execute for near-term growth while fueling the next generation of mRNA medicines for patients around the world. We are fortunate to have the privilege to make medicine at this moment in time."

Moderna is executing a strategy that balances near-term growth with long-term innovation. Building on the momentum of its four approved products -- Spikevax®, mRESVIA®, mNEXSPIKE® and mCOMBRIAX® -- the Company is driving growth through infectious disease launches, geographic expansion, and the advancement of late-stage pipeline opportunities, including its investigational intismeran autogene therapy and propionic acidemia therapeutic.

In parallel, Moderna Research and Early Development, mRED, is focused on emerging and future modalities to advance high-potential programs toward clinical proof-of-concept and first-in-human milestones. Moderna's Scientific Intelligence Engine is harnessing data, AI and machine learning, automation, and robotics to accelerate discovery and continuously improve how the Company operates.

Platform Strategy

Moderna's platform is built on three integrated pillars: mRNA science, delivery science and manufacturing processes. By combining the components of its mRNA platform, the Company creates modalities, or groups of potential mRNA medicines that share similar mRNA technologies, delivery technologies, and manufacturing processes to achieve shared product features.

These modalities turn platform expertise into repeatable development by generating proof-of-concept data from sentinel programs to de-risk modalities and accelerate development plans. Moderna has established and scaled multiple modalities, including infectious disease vaccines, intismeran autogene, and rare disease therapeutics, to validate its platform and considers these its Horizon 1 established modalities. Horizon 1 comprises Moderna's late-stage and approved products, while continuing to enable innovation in these established modalities, and drives an end-to-end path from discovery through commercialization.

Moderna Research and Early Development

Moderna Research and Early Development (mRED) builds Moderna's next growth horizons by advancing differentiated, platform-enabled modalities. Horizon 2 emerging modalities and Horizon 3 future modalities are led by mRED to scale and expand the Company's mRNA platform. Horizon 2 modalities are in the clinic and awaiting human proof-of-concept. The majority are in Phase 1/2 studies in oncology, with a multiple sclerosis therapeutic in Phase 2. Horizon 3 modalities have the potential to advance to first-in-human clinical trials by the end of 2027.

Scientific Intelligence Engine

Data from across Moderna's three Horizons powers an AI-enabled engine for accelerated discovery. This includes data generated by the Company's mRNA platform as well as internal proprietary and publicly available data. The engine feeds a continuous learning loop that helps de-risk program development through mRNA platform innovation.

Early Pipeline Progress

Highlights from Moderna's early-stage pipeline include:

Horizon 2

mRNA-4106 (Cancer antigen therapy): Encodes shared nonmutated cancer testes antigens designed to elicit T-cell immune responses against tumor cells. The Phase 1 study is ongoing with mRNA-4106 as monotherapy in advanced solid tumors.

mRNA-4200 (Cancer antigen therapy): Encodes shared nonmutated tumor associated antigens designed to elicit T-cell immune responses against tumors. The Phase 1 study is planned in combination with pembrolizumab in advanced solid tumors.

mRNA-4194 (Cancer antigen therapy): Encodes frameshift peptides frequently identified in Lynch syndrome, an inherited condition that increases cancer risk. The Phase 1/2 study is planned to start in Lynch syndrome this summer with the goal of preventing progression of pre-malignancies to cancer. mRNA-4194 represents Moderna's first investigational cancer prevention program.

mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic non-small cell lung cancer (NSCLC).

mRNA-2808 (T-cell engager): Designed to use multiplexed T-cell engagers to improve efficacy and overcome mechanisms of resistance for multiple myeloma, the Phase 1/2 study is ongoing and includes three distinct T-cell engagers against clinically validated targets.

mRNA-2151 (T-cell engager): Designed to improve anti-tumor efficacy in solid tumors, this preclinical multiplexed T-cell engager program is moving toward early development in ovarian cancer. Advancement of mRNA-2151 is supported by an encouraging early clinical signal with mRNA-2808.

mRNA-1195 (Multiple sclerosis therapeutic): Designed to address Epstein-Barr virus (EBV)-associated conditions including multiple sclerosis, the Phase 1 part B data is expected in the second half of 2026. The Phase 2 study in multiple sclerosis is ongoing; with its sentinel cohort fully enrolled, the DSMB has recommended to proceed with dose escalation.

Horizon 3

mRNA-6007 (In vivo CAR-T): Designed to enable deep B-cell depletion for autoimmune conditions using a multiplexed mRNA approach with targeted lipid nanoparticles, the program aims to deliver mRNA into immune cells in vivo, enabling transient CAR expression and potential immune reset. The initial clinical focus is systemic lupus erythematosus (SLE) and other B cell mediated autoimmune diseases.

For more details on the data and programmatic updates shared during Moderna's Science Day investor event today, please visit "Events and Presentations" in the Investors section of the Moderna website.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Spikevax®, mRESVIA®, mNEXSPIKE® and mCOMBRIAX® are registered trademarks of Moderna.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential of Moderna's mRNA platform and promise as a multi-modality biotechnology company; Moderna's potential three commercial franchises; Moderna's ability to use data, AI and machine learning, and robotics to drive innovation; anticipated infectious disease launches and geographic expansion; Moderna's late-stage pipeline opportunities in intismeran and propionic acidemia; the potential of mRNA-4194 to address Lynch syndrome and prevent cancer from occurring; Moderna's T-cell engager modality and the encouraging early clinical signal with mRNA-2808; Moderna's in vivo CAR-T modality and the potential in autoimmune diseases; Moderna's ongoing and planned clinical studies; and anticipated progress and milestones for Moderna's programs, including anticipated timing. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

###

Moderna Contacts
Media:
Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
[email protected]

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]

SOURCE: Moderna, Inc.

FDA Advisory Committee To Review Moderna Flu Vaccine ApplicationThe company submitted an application in December 2025 for mFlusiva (mRNA-1010), an mRNA-based trivalent influenza vaccine.

The VRBPAC panel’s vote will focus on the risk-benefit profile of mFlusiva for influenza prevention in adults aged 50 to 64 years, and in the 65-year-and-older population.

The briefing document released on Tuesday identified no major deficiencies.

The primary efficacy analysis demonstrated that mRNA-1010 (TIV) met all prespecified sequential success criteria—noninferiority, superiority, and super-superiority—relative to the standard-dose (SD) comparator.

Questions Around Comparator Choice And Clinical DataThe VRBPAC members will consider whether the standard-dose flu vaccine used as the control was the most appropriate comparator. High-dose, recombinant, and adjuvanted flu vaccines are generally preferred for adults 65 and older.

FDA Decision Timeline And Proposed Approval StrategyFollowing a Type A meeting, the FDA assigned a Prescription Drug User Fee Act goal date of August 5 for mRNA-1010. It’s for adults aged 50 and older.

Moderna proposed a regulatory pathway based on age, seeking full approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, along with a postmarketing requirement to conduct an additional study in older adults.

Moderna Analyst Sees Opportunity But Flags Some UncertaintiesWilliam Blair noted that the scope of Moderna's postmarketing commitments remains unclear. The company's willingness to fund potentially costly Phase IV studies are important given management's guidance to limit additional spending on its respiratory vaccine franchise.

Analyst Myles Minter said mFluSiva could become a meaningful driver of Moderna's revenue growth in 2027 if approved.

However, Minter maintained a Market Perform rating, citing the need for greater visibility into Phase 3 INTERPATH-001 data for intismeran in adjuvant melanoma, expected in 2026, which he views as a more significant long-term catalyst for the stock.

MRNA Stock Price Activity: Moderna shares rose 1.19% at $56.06 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo: pcruciatti / Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways MRNA rose over 6% after FDA briefing documents eased concerns about mFlusiva's approval prospects.FDA staff cited supporting data and no major filing deficiencies ahead of the June 18 review.VRBPAC will assess whether immunogenicity data support accelerated approval in older adults. Shares of Moderna (MRNA - Free Report) rose more than 6% on Tuesday after the FDA issued briefing documents ahead of a key advisory committee meeting, easing investor concerns about the approval prospects of the company's influenza vaccine candidate, mFlusiva (mRNA-1010).

The FDA’s Vaccines and Related Biological Products Advisory Committee (“VRBPAC”) is scheduled to meet on June 18, 2026, to assess the benefit-risk profile of the company’s influenza vaccine.

The favorable market reaction was notable because investors had braced for a more difficult regulatory review after the FDA initially declined to review Moderna's filing for the vaccine in February due to concerns related to the study design in adults aged 65 years and older. The agency later reversed course after Moderna revised its regulatory strategy for mFlusiva based on age. The regulatory filing was subsequently modified to seek traditional approval for the vaccine in adults aged 50-64 years and accelerated approval for adults aged 65 years and older.

The briefing documents were broadly constructive and significantly less negative than many investors had anticipated. The FDA staff did not identify any major deficiencies in Moderna's filing and acknowledged data supporting the vaccine.

However, one of the key questions raised by the agency relates to Moderna's proposed accelerated approval pathway for adults aged 65 years and older. The company is seeking approval in this population based on immunogenicity data rather than direct clinical efficacy evidence. The proposed pathway includes a required postmarketing confirmatory study to support full approval. However, the briefing documents specifically ask VRBPAC members to assess whether the available immunogenicity data provide a sufficient basis to predict clinical benefit in older adults.

MRNA Stock PerformanceYear to date, the stock has surged 88% against the industry’s nearly 2% fall.

Image Source: Zacks Investment Research

Why Is the VRBPAC Meeting Important for Moderna?Investors will now turn their attention to tomorrow’s VRBPAC meeting, which could provide additional insight into the FDA's comfort level with Moderna's proposed approval strategy ahead of the Aug. 5, 2026, target action date. While the agency is not obligated to follow the advisory committee's recommendations, it often aligns with its guidance, making the meeting’s outcome an important event for investors.

The outcome carries implications beyond mFlusiva itself. Moderna's long-term growth increasingly depends on expanding its respiratory portfolio beyond COVID-19 vaccines, with mFlusiva expected to serve as a foundational product within that strategy.

A favorable outcome could also provide greater regulatory clarity for mCombriax (mRNA-1083), Moderna's combination vaccine targeting both influenza and COVID-19. Moderna withdrew a filing for the vaccine last year after the FDA requested additional efficacy data related to the influenza component. Since mCombriax incorporates the same influenza component used in mFlusiva, investors will likely view any regulatory progress for the flu vaccine as an encouraging sign for the combination candidate as well. Moderna is currently awaiting further FDA guidance regarding a potential future filing for mCombriax. This combination vaccine recently secured approval in the EU.

MRNA’s Zacks RankModerna currently carries a Zacks Rank #3 (Hold).

Key Picks Among Biotech StocksSome better-ranked stocks from the sector are Immunocore (IMCR - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost nearly 19% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.66 to $4.27. INDV’s shares are up nearly 6% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.

The U.S. Food ​and Drug Administration's advisers on ‌Thursday backed approval of ​Moderna's flu ​vaccine in adults aged ⁠50 ​and older, saying ​its benefits outweigh the risks.

Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 years of age and older.

Shares of Moderna (MRNA 0.67%) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it isn't a one-trick pony by using its messenger ribonucleic acid (mRNA) platform to expand its business. Investors have noticed, and the pharmaceutical stock is up more than 100% so far this year.

Because Moderna is trading at a premium price-to-sales ratio relative to its current revenue, buying the stock now is essentially a bet that its upcoming clinical data and Food and Drug Administration (FDA) approvals will successfully unlock the commercial viability of its broader mRNA pipeline.

Here are three reasons to buy Moderna stock.

Image source: Getty Images.

1. Moderna has near-term portfolio diversification Moderna is aggressively trying to replace lost COVID-19 vaccine revenue by moving into multivalent and seasonal respiratory markets. The immediate catalyst is mFlusiva, Moderna's investigational mRNA-based seasonal influenza vaccine, which fared well in a phase 3 trial.

The FDA's target action date for the stand-alone flu vaccine is Aug. 5, following highly positive briefing documents submitted to its advisory committee. If approved, the vaccine could be available for the 2026–2027 flu season. It's not a slam dunk, as an advisory committee recently cast doubt on the methodology used in the study, though it also said it found no major deficiencies in the vaccine's efficacy.

There's also optimism regarding Moderna's flu-plus-COVID-19 combination vaccine after the vaccine, in a phase 3 trial, did better than the current stand-alone vaccines for both viruses.

Last month, the European Commission approved the vaccine, called mCOMBRIAX, which aims to simplify immunization for adults aged 50 and older by combining protection against influenza and COVID-19.

Bundling the vaccines removes a massive logistical friction point. Patients who are already sitting in a pharmacy or doctor's office chair for their annual flu shot can check both boxes at once, boosting compliance with the COVID-19 booster without requiring extra public outreach.

Today's Change

(

-0.67

%) $

-0.41

Current Price

$

60.59

2. Moderna is developing personalized cancer vaccines The most transformative upside for Moderna isn't in respiratory viruses; it's if its mRNA platform can be used to treat cancer. Moderna, in partnership with Merck, is developing intismeran autogene (mRNA-4157), an individualized cancer vaccine. The therapy uses mRNA to instruct a patient's own immune system to target specific mutations found only on their tumor cells.

In January, Moderna presented stellar five-year phase 2 data in patients with high-risk melanoma, showing sustained efficacy when combined with Keytruda. Crucially, pivotal phase 3 data readouts are expected later this year, which could pave the way for its first oncology product launch and completely redefine the company's valuation.

3. Moderna has a massive commercial expansion and runway Moderna is actively transforming its internal structure to prepare for up to three new product launches between 2027 and 2028, spanning infectious diseases (including a novel norovirus vaccine), intismeran, and rare diseases (such as its therapeutic for propionic acidemia). To manage this, it recently overhauled leadership, appointing a new veteran chief commercial officer to execute global launches.

There are some obvious risks for Moderna. In the first quarter, it reported revenue of $389 million, up 260%, year over year. However, it also reported an earnings per share (EPS) loss of $3.40, compared with $2.52 in the first quarter of 2025.

The quarter was impacted by a one-time $878 million litigation loss. Excluding that item, the company's adjusted EPS was a loss of $1.18, compared to a loss of $0.88 in the same quarter a year ago.

Moderna is obviously still burning cash on its research and development efforts, but it has $7.5 billion in cash and little debt, giving it a comfortable multiyear runway to achieve its stated goal of a companywide breakeven by 2028.

Moderna (MRNA - Free Report) closed the most recent trading day at $61.00, moving +2.79% from the previous trading session. This change outpaced the S&P 500's 1.44% loss on the day. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 2.22%.

The biotechnology company's shares have seen an increase of 26.59% over the last month, surpassing the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.

Investors will be eagerly watching for the performance of Moderna in its upcoming earnings disclosure. The company is expected to report EPS of -$2, up 6.1% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $114.89 million, down 19.09% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$8.33 per share and a revenue of $2.07 billion, indicating changes of -14.74% and +6.64%, respectively, from the former year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Moderna boasts a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 156, placing it within the bottom 37% of over 250 industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises, ​the vaccine maker said on Tuesday, as it ‌prepares for potential product launches over the next couple of years.

Moderna Inc. (NASDAQ:MRNA) announced changes to its operating model and leadership structure. The biotechnology company is preparing for potential new product launches and advancing a broad pipeline.

The company said the changes will support both its near-term and long-term objectives.

On May 1, the COVID-19 vaccine maker reported a first-quarter adjusted loss of $1.18 per share, narrower than analysts' expectations for a loss of $3.81. The adjusted figure excludes litigation-related expenses of $2.22 per share.

Revenue totaled $389 million, exceeding the consensus estimate of $227.97 million.

Moderna reiterated its goal of up to 10% revenue growth in 2026, up from $1.94 billion in 2025, and expects the 2026 revenue split to be approximately 50% U.S. and 50% international.

President Stephen Hoge Takes Expanded Oversight RoleAs part of the restructuring, Stephen Hoge will expand his responsibilities and oversee operational and cross-functional leadership across R&D, manufacturing, and commercial operations for Moderna's three franchises.

Moderna is currently managing a growing commercial portfolio, supported by four approved products in its infectious disease vaccine business.

The company is also preparing for the potential launch of up to three additional products in 2027 and 2028, including a flu-plus-COVID combination vaccine, a seasonal flu vaccine, and a norovirus vaccine.

Pipeline Progress Remains Key Focus For ModernaAlongside its commercial ambitions, Moderna said it expects several important clinical milestones this year.

These include potential pivotal data readouts for its investigational individualized neoantigen therapy, Intismeran autogene, and its therapeutic candidate for propionic acidemia, a rare genetic disease.

Positive outcomes could support the launch of the company's first oncology and rare disease products.

MRNA Stock Price Activity: Moderna shares were up 6.35% at $55.44 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.